SuperworthAligos Therapeutics shares outstanding ALGS
Diluted shares outstanding, averaged over each quarter, from 2019.
- Latest quarter, to Jun 30, 2026
- 10.4M
- On a year earlier
- +0.8%
- more shares
Aligos Therapeutics had 10.4M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 0.8% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 10.4M | +65% |
| FY2024 | 6.3M | +25% |
| FY2023 | 5M | +194% |
| FY2022 | 1.7M | +2% |
| FY2021 | 1.7M | +1599% |
| FY2019 | 98.7K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 10.4M | +1% | |
| Q1 FY26 | 10.4M | +19% | |
| Q4 FY25 | 10.4M | +65% | |
| Q3 FY25 | 10.4M | +65% | |
| Q2 FY25 | 10.4M | +65% | |
| Q1 FY25 | 8.7M | +39% | |
| Q4 FY24 | 6.3M | +25% | |
| Q3 FY24 | 6.3M | +261% | |
| Q2 FY24 | 6.3M | +262% | |
| Q1 FY24 | 6.2M | +264% | |
| Q4 FY23 | 5M | +194% | |
| Q3 FY23 | 1.7M | +2% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Aligos Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.